hologic , inc .notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) the acquisition also provides for up to two annual earn out payments not to exceed $ 15000 in the aggregate based on biolucent 2019s achievement of certain revenue targets .the company has considered the provision of eitf issue no .95-8 , accounting for contingent consideration paid to the shareholders of and acquired enterprise in a purchase business combination , and concluded that this contingent consideration will represent additional purchase price .as a result , goodwill will be increased by the amount of the additional consideration , if any , when it becomes due and payable .the allocation of the purchase price is based upon preliminary estimates of the fair value of assets acquired and liabilities assumed as of september 18 , 2007 .the company is in the process of gathering information to finalize its valuation of certain assets and liabilities .the purchase price allocation will be finalized once the company has all necessary information to complete its estimate , but generally no later than one year from the date of acquisition .the components and initial allocation of the purchase price , consists of the following approximate amounts: .
[['net tangible assets acquired as of september 18 2007', '$ 2800'], ['developed technology and know how', '12300'], ['customer relationship', '17000'], ['trade name', '2800'], ['deferred income tax liabilities net', '-9500 ( 9500 )'], ['goodwill', '47800'], ['estimated purchase price', '$ 73200']]
as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued .it was determined that only customer relationship , trade name and developed technology and know how had separately identifiable values .the fair value of these intangible assets was determined through the application of the income approach .customer relationship represents a large customer base that are expected to purchase this disposable product on a regular basis .trade name represents the biolucent product names that the company intends to continue to use .developed technology and know how represents currently marketable purchased products that the company continues to sell as well as utilize to enhance and incorporate into the company 2019s existing products .the deferred income tax liability relates to the tax effect of acquired identifiable intangible assets , and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes partially offset by acquired net operating loss carryforwards of approximately $ 2400 .fiscal 2006 acquisitions : on may 2 , 2006 , the company acquired 100% ( 100 % ) of the outstanding voting stock of aeg elektrofotografie gmbh and its group of related companies ( aeg ) .the results of operations for aeg have been included in the company 2019s consolidated financial statements from the date of acquisition as part of its other business segment .the company has concluded that the acquisition of aeg does not represent a material business combination and therefore no pro forma financial information has been provided herein .aeg specializes in the manufacture of photoconductor materials for use in a variety of electro photographic applications including for the coating of the company 2019s digital detectors .the acquisition of aeg allows the company to have control over a critical step in its detector manufacturing process 2014to more efficiently manage .

Question: what portion of the estimated purchase price is derived by the net tangible assets?
Answer: 3.8%